Abstract
Overview
Introduction
This analysis examines the historical and forecast performance for Cephalon in
the ethical pharmaceutical sector. The profile encompasses global company
strategy, portfolio and pipeline analysis and assessment of financial
performance, with 1-6 year sales forecasts for key drugs. An interactive
forecasting and analysis tool provides continually updated quantitative and
qualitative information.
Reasons to Purchase
- Benchmark Cephalon' s performance against key rivals in the ethical
pharmaceutical sector
- See how Cephalon' s future performance relies heavily on the successful
product lifecycle management of leading products Actiq and Provigil
- Learn how Cephalon has targeted the high-growth oncology therapy area, in
order to diversify its portfolio
View Cart
